Intrexon (XON) Drops 9.01% on January 06

Equities Staff |

Intrexon (XON) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 9.01% to $26.02, a loss of $-2.575 per share. Starting at an opening price of $27.94 a share, the stock traded between $25.06 and $28.50 over the course of the trading day. Volume was 1.87 million shares over 12,123 trades, against an average daily volume of 1.93 million shares and a total float of 116.4 million.

The losses send Intrexon down to a market cap of $3.03 billion. In the last year, Intrexon has traded between $69.45 and $25.23, and its 50-day SMA is currently $34.17 and 200-day SMA is $42.18.

Intrexon Corp is a synthetic biology company that designs, builds and regulates gene programs using its proprietary and complementary technologies.

Intrexon is based out of Germantown, MD and has some 558 employees. Its CEO is Randal J. Kirk.

For a complete fundamental analysis analysis of Intrexon, check out’s Stock Valuation Analysis report for XON. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…